ZeaVision launches online campaign to raise awareness on Age-related Macular Degeneration

ZeaVision, LLC launched a unique online campaign to increase awareness about Age-related Macular Degeneration during February for AMD Awareness Month.

Directed toward individual consumers as well as EyeCare Professionals, the company has issued the "AMD Challenge" at http://www.amdchallenge.com. At the website, visitors play a scratch-off game that shows what it looks like to have AMD, associated risk factors, along with the chance to win a variety of prizes.

Chris Barber, VP of Sales and Marketing at ZeaVision explains, "As the company that patented Zeaxanthin for rebuilding macular pigment in the eye, we have business and social interests in creating awareness around this debilitating disease. People can see what AMD looks like and learn about the risk factors in a fun and interactive way by taking the AMD Challenge at http://www.amdchallenge.com."

Age-related Macular Degeneration (AMD) affects millions of people every year and is the leading cause of blindness in people over age 55. AMD affects the macula - the part of the retina responsible for central vision. The disease is growing at an alarming rate, and education is the first step in fighting AMD. Everyone is encouraged to learn more about the risk factors at http://www.amdchallenge.com. For more information on AMD, please visit ZeaVision's website, http://www.zeavision.com.

ZeaVision and its founders have conducted nearly 20 years of research and development and hold patents on Zeaxanthin, a natural antioxidant derived from paprika peppers and shown to increase macular pigment levels. The company also offers a state-of-the-art testing device as part of its Eye-Q Intelligent AMD Risk Management program. The measurement device, QuantifEYE(R), measures macular pigment optical density and allows EyeCare Professionals to measure, manage, monitor, and maintain healthy macular pigment levels, an important AMD risk factor.

Source:

ZeaVision, LLC

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Johns Hopkins study offers new hope for wet AMD patients